Turn Therapeutics Inc. (TTRX) Key Metrics
TTRX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $321.0M
- Enterprise value
- $406.1M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 597.3
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
TTRX key metrics, 2022–2025
Fiscal year ended December 31, 2025 · U.S. dollarsTTRX returns How much profit the business earns on the capital it uses.
TTRX per-share figures Results divided by the shares outstanding at year-end.
TTRX financial health Debt, liquidity and how easily interest is covered.
TTRX valuation history
TTRX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
TTRX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
TTRX price vs earnings per share
TTRX key metrics
2022–2025| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Valuation | ||||
| Market capitalization | $54.2M | — | — | — |
| Enterprise value | $49.2M | — | — | — |
| Price / book | 11.6 | — | — | — |
| Earnings yield | −5.9% | — | — | — |
| Free cash flow yield | −5.0% | — | — | — |
| Share price at fiscal year-end | $3.94 | — | — | — |
| Per share | ||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$0.23 | −$0.13 | −$0.17 | −$0.33 |
| Operating cash flow per share | −$0.19 | −$0.10 | −$0.10 | −$0.09 |
| Free cash flow per share | −$0.20 | −$0.11 | −$0.11 | −$0.09 |
| Cash per share | $0.37 | $0.07 | $0.09 | $0.16 |
| Book value per share | $0.34 | −$0.01 | $0.01 | $0.09 |
| Tangible book value per share | $0.27 | −$0.07 | −$0.05 | $0.03 |
| Capex per share | $0.01 | $0.01 | $0.00 | $0.00 |
| Debt per share | $0.01 | $0.01 | $0.00 | $0.01 |
| Shares outstanding | 13.7M | 13.4M | 13.2M | 13.2M |
| Change in shares outstanding | +2.4% | +1.3% | +0.5% | — |
| Returns & profitability | ||||
| Return on equity (ROE) | −141.7% | — | −369.4% | −371.1% |
| Return on assets (ROA) | −45.0% | −87.1% | −93.0% | −147.1% |
| Return on tangible assets | −28.4% | −144.1% | −184.3% | −193.5% |
| Financial health | ||||
| Total debt | $80,376 | $121,036 | $25,156 | $83,669 |
| Cash & short-term investments | $5.1M | $872,599 | $1.2M | $2.1M |
| Net debt | −$5.0M | −$751,563 | −$1.2M | −$2.0M |
| Debt / equity | 0.02 | — | 0.29 | 0.07 |
| Debt / assets | 0.01 | 0.06 | 0.01 | 0.03 |
| Current ratio | 0.87 | 1.55 | 2.45 | 1.23 |
| Quick ratio | 0.87 | 1.55 | 2.45 | 1.23 |
| Interest coverage | — | — | — | -49.3 |
| Working capital | −$806,980 | $389,992 | $712,038 | $401,442 |
| Invested capital | −$309,045 | −$928,995 | −$1.1M | −$864,120 |
| Tangible asset value | $3.8M | −$999,363 | −$684,171 | $457,199 |
| Net current asset value | −$2.3M | −$1.1M | −$725,975 | $367,239 |
| Graham net-net per share | −$0.17 | −$0.10 | −$0.06 | $0.03 |
| Capital allocation | ||||
| Capex / depreciation | 2.90 | 2.09 | 1.01 | 0.00 |
| Efficiency | ||||
| Days payables outstanding | — | — | — | 1,771.5 |
| Payables turnover | — | — | — | 0.21 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $2.9M | — | — | $255,960 |
| Intangibles / total assets | 7.6% | 40.1% | 38.2% | 24.0% |
Computed from TTRX's annual financial statements (latest annual report filed March 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
TTRX valuation and financial ratios
Turn Therapeutics earned a return on equity of −141.7% in fiscal 2025. It ended the year with $0.1 million of debt and $5.1 million in cash and short-term investments, a net cash position of $5.0 million.
See the TTRX income statement, the TTRX chart for price history, or the TTRX stock overview for the latest quote and news.
TTRX key metrics FAQ
What is Turn Therapeutics's return on equity?
Turn Therapeutics's return on equity (ROE) was −141.7% in fiscal 2025: net income of -$3.2 million on average shareholders' equity of $2.3 million.
How much debt does Turn Therapeutics have?
Turn Therapeutics had total debt of $0.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.02 and more cash than debt.
What is Turn Therapeutics's free cash flow yield?
Turn Therapeutics generated -$2.7 million of free cash flow in fiscal 2025, a free cash flow yield of −5.0% on its market value at year-end ($54.2 million).
What is Turn Therapeutics's current ratio?
Turn Therapeutics's current ratio was 0.87 at the end of fiscal 2025: current assets were 0.87 times current liabilities.